Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles
- PMID: 9700655
- DOI: 10.1007/978-3-7091-6467-9_15
Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles
Abstract
Alzheimer disease (AD) has polyetiology. Independent of the etiology the disease is characterized histopathologically by the intraneuronal accumulation of paired helical filaments (PHF), forming neurofibrillary tangles, neuropil threads and dystrophic neurites surrounding the extracellular deposits of beta-amyloid in plaques, the second major lesion. The clincal expression of AD correlates with the presence of neurofibrillary degeneration; beta-amyloid alone does not produce the disease clinically. Thus arresting neurofibrillary degeneration offers a promising key target for therapeutic intervention of AD. The major protein subunit of PHF is the microtubule-associated protein tau. Tau in AD brain, especially PHF, is abnormally hyperphosphorylated and glycosylated. With maturation, the tangles are increasingly ubiquitinated. Levels of tau and conjugated ubiquitin are elevated both in AD brain and CSF. The AD abnormally phosphorylated tau (AD P-tau) does not promote microtubule assembly, but on dephosphorylation its microtubule promoting activity is restored to approximately that of the normal tau. The AD P-tau competes with tubulin in binding to normal tau, MAP1 and MAP2 and inhibits their microtubule assembly promoting activities. Furthermore, the AD P-tau sequesters normal MAPs from microtubules. The association of AD P-tau with normal tau but not with MAP1 or MAP2 results in the formation of tangles of 3.3 +/- 0.5 mm filaments. Deglycosylation of Alzheimer neurofibrillary tangles with endoglycosidase F/N-glycosidase F untwists the PHF resulting in tangles of thin filaments similar to those formed by association between the AD P-tau and normal tau. Dephosphorylation or deglycosylation plus dephosphorylation but not deglycosylation alone restores the microtubule assembly promoting activity of tau. In vitro AD P-tau can be dephosphorylated by protein phosphatases PP-2B, PP-2A and PP-1 but not PP-2C and all the three tau phosphatases are present in brain neurons. Tau phosphatase activity is decreased by approximately 30% in AD brain. Inhibition of PP-2A and PP-1 activities in SY5Y neuroblastoma by 10 nM okadaic acid causes breakdown of microtubules and the degeneration of these cells. It is suggested (I) that a defect(s) in the protein phosphorylation/dephosphorylation system(s) leads to a hyperphosphorylation of tau, (ii) that this altered tau causes disassembly of microtubules and consequently a retrograde neuronal degeneration; (iii) a pharmacological approach to AD is to enhance the tau phosphatase activity; and (iv) that CSF tau and conjugated ubiquitin levels are promising markers of AD brain pathology.
Similar articles
-
Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach.J Neural Transm Suppl. 2000;59:213-22. doi: 10.1007/978-3-7091-6781-6_22. J Neural Transm Suppl. 2000. PMID: 10961432 Review.
-
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.Eur J Neurosci. 2007 Jan;25(1):59-68. doi: 10.1111/j.1460-9568.2006.05226.x. Eur J Neurosci. 2007. PMID: 17241267 Free PMC article.
-
Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention.J Cell Mol Med. 2008 Jan-Feb;12(1):38-55. doi: 10.1111/j.1582-4934.2008.00225.x. Epub 2007 Jan 9. J Cell Mol Med. 2008. PMID: 18194444 Free PMC article. Review.
-
Pharmacological targets to inhibit Alzheimer neurofibrillary degeneration.J Neural Transm Suppl. 2002;(62):309-19. doi: 10.1007/978-3-7091-6139-5_29. J Neural Transm Suppl. 2002. PMID: 12456074 Review.
-
Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion.J Mol Neurosci. 2002 Aug-Oct;19(1-2):95-9. doi: 10.1007/s12031-002-0017-3. J Mol Neurosci. 2002. PMID: 12212801 Review.
Cited by
-
Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures.Mol Neurobiol. 2016 Jul;53(5):3338-3348. doi: 10.1007/s12035-015-9272-5. Epub 2015 Jun 17. Mol Neurobiol. 2016. PMID: 26081146
-
Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways.BMC Neurosci. 2015 Oct 23;16:69. doi: 10.1186/s12868-015-0211-1. BMC Neurosci. 2015. PMID: 26499115 Free PMC article. Review.
-
Primate-specific 82-kDa choline acetyltransferase attenuates progression of Alzheimer's disease-like pathology in the APPNL-G-F knock-in mouse model.Sci Rep. 2024 Nov 11;14(1):27614. doi: 10.1038/s41598-024-78751-2. Sci Rep. 2024. PMID: 39528509 Free PMC article.
-
The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain.Arch Immunol Ther Exp (Warsz). 2012 Aug;60(4):251-66. doi: 10.1007/s00005-012-0181-2. Epub 2012 Jun 19. Arch Immunol Ther Exp (Warsz). 2012. PMID: 22710659 Free PMC article. Review.
-
Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality.J Am Chem Soc. 2023 Feb 8:10.1021/jacs.2c11706. doi: 10.1021/jacs.2c11706. Online ahead of print. J Am Chem Soc. 2023. PMID: 36753634 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous